Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck

Corrado Boni, Gabriella Moretti, Luisa Savoldi, Luciano Armaroli, Werter Barbieri, Giancarlo Bisagni, Angelo Caroggio, Cinzia Iotti, Corrado Pedroni, Anna Lucia Manenti, Ermanno Rondini, Maurizio Sassi, Alvise Zadro

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims and background: The aim of the study was to assess the activity and the toxicity of cisplatin (DDP) and fluorouracil (FU) administered by continuous infusion as neoadjuvant chemotherapy for patients with stage II-IV, M0 squamous cell carcinoma of the head and neck. Methods: Thirty previously untreated patients were submitted to chemotherapy with DDP (20 mg/m2) and FU (1000 mg/m2), both in continuous infusion for 5 days, repeated every 21 days, for a maximum of 5 cycles. Following completion of chemotherapy, the patients underwent radiotherapy; in some patients surgery was performed immediately after chemotherapy. All patients were monitored for response, time to failure, survival, treatment-related events and toxicity. Results: All patients were evaluated for response; after chemotherapy the complete response rate was 27% and the partial response rate 33%. Twenty-four patients underwent radiotherapy: the overall response rate was 83% (complete response 79%). After a median follow-up of 34 months, the median survival time was 22 months with a median time to failure of 15 months. Acute vascular accidents were the main and unexpected adverse events, with 2 deaths for pulmonary embolism and 1 for stroke. The response rate to the regimen does not seem to be better than that obtained with the standard combination of cisplatin bolus and fluorouracil continuous infusion. The disadvantage of the regimen is that it causes more discomfort for the patient in that it requires hospitalization. Conclusions: For this reason, we believe that there are no elements for recommending the schedule as neoadjuvant treatment of patients with squamous cell carcinoma of the head and neck or as an experimental arm in a randomized trial.

Original languageEnglish
Pages (from-to)567-572
Number of pages6
JournalTumori
Volume82
Issue number6
Publication statusPublished - Nov 1996

Fingerprint

Fluorouracil
Cisplatin
Drug Therapy
Radiotherapy
Carcinoma, squamous cell of head and neck
Neoadjuvant Therapy
Survival
Treatment Failure
Pulmonary Embolism
Reaction Time
Accidents
Blood Vessels
Appointments and Schedules
Hospitalization
Stroke

Keywords

  • cisplatin continuous infusion
  • head and neck carcinona
  • neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck. / Boni, Corrado; Moretti, Gabriella; Savoldi, Luisa; Armaroli, Luciano; Barbieri, Werter; Bisagni, Giancarlo; Caroggio, Angelo; Iotti, Cinzia; Pedroni, Corrado; Manenti, Anna Lucia; Rondini, Ermanno; Sassi, Maurizio; Zadro, Alvise.

In: Tumori, Vol. 82, No. 6, 11.1996, p. 567-572.

Research output: Contribution to journalArticle

Boni, C, Moretti, G, Savoldi, L, Armaroli, L, Barbieri, W, Bisagni, G, Caroggio, A, Iotti, C, Pedroni, C, Manenti, AL, Rondini, E, Sassi, M & Zadro, A 1996, 'Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck', Tumori, vol. 82, no. 6, pp. 567-572.
Boni, Corrado ; Moretti, Gabriella ; Savoldi, Luisa ; Armaroli, Luciano ; Barbieri, Werter ; Bisagni, Giancarlo ; Caroggio, Angelo ; Iotti, Cinzia ; Pedroni, Corrado ; Manenti, Anna Lucia ; Rondini, Ermanno ; Sassi, Maurizio ; Zadro, Alvise. / Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck. In: Tumori. 1996 ; Vol. 82, No. 6. pp. 567-572.
@article{23a4c49e6d744ff3a13cd0e9873298ac,
title = "Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck",
abstract = "Aims and background: The aim of the study was to assess the activity and the toxicity of cisplatin (DDP) and fluorouracil (FU) administered by continuous infusion as neoadjuvant chemotherapy for patients with stage II-IV, M0 squamous cell carcinoma of the head and neck. Methods: Thirty previously untreated patients were submitted to chemotherapy with DDP (20 mg/m2) and FU (1000 mg/m2), both in continuous infusion for 5 days, repeated every 21 days, for a maximum of 5 cycles. Following completion of chemotherapy, the patients underwent radiotherapy; in some patients surgery was performed immediately after chemotherapy. All patients were monitored for response, time to failure, survival, treatment-related events and toxicity. Results: All patients were evaluated for response; after chemotherapy the complete response rate was 27{\%} and the partial response rate 33{\%}. Twenty-four patients underwent radiotherapy: the overall response rate was 83{\%} (complete response 79{\%}). After a median follow-up of 34 months, the median survival time was 22 months with a median time to failure of 15 months. Acute vascular accidents were the main and unexpected adverse events, with 2 deaths for pulmonary embolism and 1 for stroke. The response rate to the regimen does not seem to be better than that obtained with the standard combination of cisplatin bolus and fluorouracil continuous infusion. The disadvantage of the regimen is that it causes more discomfort for the patient in that it requires hospitalization. Conclusions: For this reason, we believe that there are no elements for recommending the schedule as neoadjuvant treatment of patients with squamous cell carcinoma of the head and neck or as an experimental arm in a randomized trial.",
keywords = "cisplatin continuous infusion, head and neck carcinona, neoadjuvant chemotherapy",
author = "Corrado Boni and Gabriella Moretti and Luisa Savoldi and Luciano Armaroli and Werter Barbieri and Giancarlo Bisagni and Angelo Caroggio and Cinzia Iotti and Corrado Pedroni and Manenti, {Anna Lucia} and Ermanno Rondini and Maurizio Sassi and Alvise Zadro",
year = "1996",
month = "11",
language = "English",
volume = "82",
pages = "567--572",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck

AU - Boni, Corrado

AU - Moretti, Gabriella

AU - Savoldi, Luisa

AU - Armaroli, Luciano

AU - Barbieri, Werter

AU - Bisagni, Giancarlo

AU - Caroggio, Angelo

AU - Iotti, Cinzia

AU - Pedroni, Corrado

AU - Manenti, Anna Lucia

AU - Rondini, Ermanno

AU - Sassi, Maurizio

AU - Zadro, Alvise

PY - 1996/11

Y1 - 1996/11

N2 - Aims and background: The aim of the study was to assess the activity and the toxicity of cisplatin (DDP) and fluorouracil (FU) administered by continuous infusion as neoadjuvant chemotherapy for patients with stage II-IV, M0 squamous cell carcinoma of the head and neck. Methods: Thirty previously untreated patients were submitted to chemotherapy with DDP (20 mg/m2) and FU (1000 mg/m2), both in continuous infusion for 5 days, repeated every 21 days, for a maximum of 5 cycles. Following completion of chemotherapy, the patients underwent radiotherapy; in some patients surgery was performed immediately after chemotherapy. All patients were monitored for response, time to failure, survival, treatment-related events and toxicity. Results: All patients were evaluated for response; after chemotherapy the complete response rate was 27% and the partial response rate 33%. Twenty-four patients underwent radiotherapy: the overall response rate was 83% (complete response 79%). After a median follow-up of 34 months, the median survival time was 22 months with a median time to failure of 15 months. Acute vascular accidents were the main and unexpected adverse events, with 2 deaths for pulmonary embolism and 1 for stroke. The response rate to the regimen does not seem to be better than that obtained with the standard combination of cisplatin bolus and fluorouracil continuous infusion. The disadvantage of the regimen is that it causes more discomfort for the patient in that it requires hospitalization. Conclusions: For this reason, we believe that there are no elements for recommending the schedule as neoadjuvant treatment of patients with squamous cell carcinoma of the head and neck or as an experimental arm in a randomized trial.

AB - Aims and background: The aim of the study was to assess the activity and the toxicity of cisplatin (DDP) and fluorouracil (FU) administered by continuous infusion as neoadjuvant chemotherapy for patients with stage II-IV, M0 squamous cell carcinoma of the head and neck. Methods: Thirty previously untreated patients were submitted to chemotherapy with DDP (20 mg/m2) and FU (1000 mg/m2), both in continuous infusion for 5 days, repeated every 21 days, for a maximum of 5 cycles. Following completion of chemotherapy, the patients underwent radiotherapy; in some patients surgery was performed immediately after chemotherapy. All patients were monitored for response, time to failure, survival, treatment-related events and toxicity. Results: All patients were evaluated for response; after chemotherapy the complete response rate was 27% and the partial response rate 33%. Twenty-four patients underwent radiotherapy: the overall response rate was 83% (complete response 79%). After a median follow-up of 34 months, the median survival time was 22 months with a median time to failure of 15 months. Acute vascular accidents were the main and unexpected adverse events, with 2 deaths for pulmonary embolism and 1 for stroke. The response rate to the regimen does not seem to be better than that obtained with the standard combination of cisplatin bolus and fluorouracil continuous infusion. The disadvantage of the regimen is that it causes more discomfort for the patient in that it requires hospitalization. Conclusions: For this reason, we believe that there are no elements for recommending the schedule as neoadjuvant treatment of patients with squamous cell carcinoma of the head and neck or as an experimental arm in a randomized trial.

KW - cisplatin continuous infusion

KW - head and neck carcinona

KW - neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=12644278833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12644278833&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 567

EP - 572

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -